Medicamen Organ.

{
  "main_header": {
    "sid": 10039294,
    "name": "Medicamen Organ.",
    "stock_name": "Medicamen Organ.",
    "full_name": "Medicamen Organics Ltd",
    "name_url": "stocks-analysis/medicamen-organ",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "27.45",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "27.45",
    "mcapval": "32.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "MEDIORG",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0PE401018",
    "curr_date": "Feb 12",
    "curr_time": "",
    "bse_nse_vol": 42000,
    "exc_status": "Active",
    "traded_date": "Feb 12, 2026",
    "traded_date_str": "2026 02 12",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/medicamen-organ-10039294-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Medicamen Organ. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-medicamen-organ-overvalued-or-undervalued-3745687",
        "imagepath": "",
        "date": "2025-12-04 08:47:14",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Current Valuation Metrics Indicate Attractiveness</strong></p>\n<p>Medicamen Organ. trades at a price-to-earnings (PE) ratio of approximately 9.6, which is notably low compared to many of its pharmaceutical peers. Its price-to-book value stands near 1.02, suggesting the stock is priced close to its net asset value. The enterprise value (EV) to EBITDA ratio of 7.9 further supports the notion of an attractively valued stock, especially when benchmarked against sector averages.</p>\n<p>Return on capital employed (ROCE) and return on equity (ROE) are healthy at 11.1% and 10.6% respectively, indicating efficient utilisation of capital and shareholder funds. These profitability metrics, combined with modest valuation multiples, suggest that the company is not overpriced relative to its earnings and ..."
      },
      {
        "title": "Is Medicamen Organ. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-medicamen-organ-overvalued-or-undervalued-3716797",
        "imagepath": "",
        "date": "2025-11-20 08:07:45",
        "description": "As of 19 November 2025, Medicamen Organ. has moved from a fair to an attractive valuation grade, indicating a positive shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 9.80, an EV to EBITDA of 8.02, and a Price to Book Value of 1.04. These ratios suggest that the stock is trading at a significant discount compared to its earnings and assets.\n\nIn comparison to its peers, Medicamen Organ. stands out with a much lower PE ratio than Sun Pharma. Industries at 37.07 and Divi's Lab at 68.85, both of which are classified as expensive. Additionally, while Cipla and Dr. Reddy's Labs are also attractive, their PE ratios of 22.64 and 18.06, respectively, are still considerably higher than that of Medicamen. The company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -49.17% compared to the Sensex's 10.18%, reinforcing the notion tha..."
      },
      {
        "title": "Is Medicamen Organ. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-medicamen-organ-overvalued-or-undervalued-3713674",
        "imagepath": "",
        "date": "2025-11-19 08:10:48",
        "description": "As of 18 November 2025, the valuation grade for Medicamen Organ. has moved from attractive to fair. The company is currently fairly valued, with a PE ratio of 10.32, an EV to EBITDA of 8.33, and a ROCE of 11.09%. In comparison to its peers, Sun Pharma. is considered expensive with a PE ratio of 36.56, while Cipla is attractive with a PE ratio of 22.49.\n\nDespite its fair valuation, Medicamen Organ. has underperformed significantly, with a year-to-date return of -46.47% compared to a 9.58% return for the Sensex. This underperformance highlights the potential concerns surrounding the company's growth prospects relative to its peers in the pharmaceuticals and biotechnology sector...."
      },
      {
        "title": "Is Medicamen Organ. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-medicamen-organ-overvalued-or-undervalued-3710005",
        "imagepath": "",
        "date": "2025-11-18 08:26:42",
        "description": "As of 17 November 2025, Medicamen Organ. has moved from a fair to an attractive valuation grade. The company appears to be undervalued, particularly when considering its key ratios: a PE ratio of 9.84, an EV to EBITDA of 7.39, and a ROCE of 12.71%. In comparison to its peers, Medicamen's valuation is significantly lower than Sun Pharma's PE ratio of 36.69 and Divi's Lab's PE ratio of 69.78, which are categorized as very expensive.\n\nDespite the attractive valuation, Medicamen has faced substantial stock declines, with a year-to-date return of -48.98%, contrasting sharply with the Sensex's positive return of 10.02%. This divergence suggests that the market may not fully recognize the company's potential, reinforcing the conclusion that Medicamen Organ. is undervalued in the current market environment...."
      }
    ],
    "total": 191,
    "sid": "10039294",
    "stock_news_url": "https://www.marketsmojo.com/news/medicamen-organics-10039294"
  },
  "announcements": "",
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Medicamen Organ. overvalued or undervalued?

2025-12-04 08:47:14

Current Valuation Metrics Indicate Attractiveness

Medicamen Organ. trades at a price-to-earnings (PE) ratio of approximately 9.6, which is notably low compared to many of its pharmaceutical peers. Its price-to-book value stands near 1.02, suggesting the stock is priced close to its net asset value. The enterprise value (EV) to EBITDA ratio of 7.9 further supports the notion of an attractively valued stock, especially when benchmarked against sector averages.

Return on capital employed (ROCE) and return on equity (ROE) are healthy at 11.1% and 10.6% respectively, indicating efficient utilisation of capital and shareholder funds. These profitability metrics, combined with modest valuation multiples, suggest that the company is not overpriced relative to its earnings and ...

Read full news article

Is Medicamen Organ. overvalued or undervalued?

2025-11-20 08:07:45

As of 19 November 2025, Medicamen Organ. has moved from a fair to an attractive valuation grade, indicating a positive shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 9.80, an EV to EBITDA of 8.02, and a Price to Book Value of 1.04. These ratios suggest that the stock is trading at a significant discount compared to its earnings and assets. In comparison to its peers, Medicamen Organ. stands out with a much lower PE ratio than Sun Pharma. Industries at 37.07 and Divi's Lab at 68.85, both of which are classified as expensive. Additionally, while Cipla and Dr. Reddy's Labs are also attractive, their PE ratios of 22.64 and 18.06, respectively, are still considerably higher than that of Medicamen. The company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -49.17% compared to the Sensex's 10.18%, reinforcing the notion tha...

Read full news article

Is Medicamen Organ. overvalued or undervalued?

2025-11-19 08:10:48

As of 18 November 2025, the valuation grade for Medicamen Organ. has moved from attractive to fair. The company is currently fairly valued, with a PE ratio of 10.32, an EV to EBITDA of 8.33, and a ROCE of 11.09%. In comparison to its peers, Sun Pharma. is considered expensive with a PE ratio of 36.56, while Cipla is attractive with a PE ratio of 22.49. Despite its fair valuation, Medicamen Organ. has underperformed significantly, with a year-to-date return of -46.47% compared to a 9.58% return for the Sensex. This underperformance highlights the potential concerns surrounding the company's growth prospects relative to its peers in the pharmaceuticals and biotechnology sector....

Read full news article

Is Medicamen Organ. overvalued or undervalued?

2025-11-18 08:26:42

As of 17 November 2025, Medicamen Organ. has moved from a fair to an attractive valuation grade. The company appears to be undervalued, particularly when considering its key ratios: a PE ratio of 9.84, an EV to EBITDA of 7.39, and a ROCE of 12.71%. In comparison to its peers, Medicamen's valuation is significantly lower than Sun Pharma's PE ratio of 36.69 and Divi's Lab's PE ratio of 69.78, which are categorized as very expensive. Despite the attractive valuation, Medicamen has faced substantial stock declines, with a year-to-date return of -48.98%, contrasting sharply with the Sensex's positive return of 10.02%. This divergence suggests that the market may not fully recognize the company's potential, reinforcing the conclusion that Medicamen Organ. is undervalued in the current market environment....

Read full news article

View All News